NCT05308446 2026-04-13
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting
NCT05710406 2026-01-26
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 2/3 Active not recruiting
NCT03803553 2025-12-23
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
Phase 3 Recruiting
NCT04017650 2025-11-20
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05510895 2025-10-01
NeoBRAF
AIO-Studien-gGmbH
Phase 2 Completed
NCT07178717 2025-09-17
REFISH
Vall d'Hebron Institute of Oncology
Phase 2 Not yet recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT06640166 2025-02-12
ECLYPse
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Recruiting
NCT04044430 2023-01-09
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
University of California, San Francisco
Phase 1 Terminated